Therefore, while we have tested a number of hypotheses addressing the underlying resistance mechanism in our Brca2 loss-of-function mammary tumour model, including upregulation of P-gp, altered PD/PK, loss of expression of the drug target and restoration of HRR, none of these hypotheses can be supported. This evidence concerns the gene BRCA2 and breast cancer.